Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2014 03:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer

- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients - - Detailed Results Presented at the International Gynecologic Cancer Society Meeting -...
October 22, 2014 09:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will hold a...
October 07, 2014 16:01 ET | Source: Mateon Therapeutics

OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has...
October 06, 2014 16:01 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society

SOUTH SAN FRANCISCO, Calif., Oct. 6, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the data from the...
September 17, 2014 16:01 ET | Source: Mateon Therapeutics

OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient...
August 26, 2014 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
August 05, 2014 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2014 Financial Results

- Phase 2 Trial of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors Planned - - Further Data from Gynecologic Oncology Group (GOG) Phase 2 Ovarian Cancer Trial to be Presented in November...
July 23, 2014 16:30 ET | Source: Mateon Therapeutics

OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second...
May 23, 2014 09:00 ET | Source: Mateon Therapeutics

OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., May 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that it has entered into...
May 16, 2014 08:30 ET | Source: Mateon Therapeutics

OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., May 16, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...